Semaglutide vs. Tirzepatide: Understanding the Differences

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide acts at both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Those differences in mechanism are one reason the medications are studied separately rather than treated as interchangeable. The medication that is medically appropriate for an individual depends on more than mechanism alone.

SURMOUNT-5 directly compared once-weekly tirzepatide with once-weekly semaglutide in 751 adults with obesity who did not have type 2 diabetes. Participants received the maximum tolerated doses specified in the trial for 72 weeks. At week 72, the mean percentage change in body weight was -20.2% with tirzepatide and -13.7% with semaglutide. Gastrointestinal adverse events were the most common in both groups and occurred primarily during dose escalation. These are clinical-trial averages from a defined population and regimen. They are not a forecast of what any one person will experience.

A clinician still has to consider the full clinical picture: medical history, contraindications and warnings, other medications, prior treatment experience, tolerability, treatment goals, formulation and route, access and cost, and other individual factors. The right question is not simply “Which drug produced the larger average?” It is “Which option, if any, fits this patient’s medical needs and circumstances?”

SURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Its results should not be presented as evidence that every compounded preparation containing a similarly named ingredient will produce the same outcomes. When you see a percentage or comparison online, look for the exact study, population, treatment duration, formulations and doses studied, and the source.

Baseline means understanding where you are starting: health history, goals, medications and appropriate measurements or testing. Path means working with a licensed healthcare professional to select an individualized plan. Progress means monitoring response, tolerability and relevant health measures over time. That framework keeps one trial number from becoming the entire decision.